Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Multiple Sclerosis

Free Subscription 13.04.2026 3 Ann Neurol 1 Brain 1 J Neuroimmunol 3 J Neurol 1 J Neurol Sci 2 Mult Scler 1 Nat Rev Neurol 3 Neurology 4 Rev Neurol (Paris)

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Neurol

1. GERNERT JA, Bartos LM, Christmann T, Zausinger H, et al
   Hyperreflective Foci in the Inner Nuclear Layer: Proof-of-Concept for an Optical Coherence Tomography Derived Microglia-Related Marker in Multiple Sclerosis.
   Ann Neurol. 2026 Apr 7. doi: 10.1002/ana.78215.
   PubMed         Abstract available
   
   
2. CERONO G, Cree BAC, Hauser SL, Baranzini SE, et al
   Reply to "Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real-World Evidence".
   Ann Neurol. 2026 Apr 7. doi: 10.1002/ana.78222.
   PubMed        
   
   
3. COPELAND TP
   Letter Concerning Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real-World Evidence.
   Ann Neurol. 2026 Apr 7. doi: 10.1002/ana.78218.
   PubMed        
   
   

   
   Brain

4. AGUZZI EA, Desai RA, Yang Z, Davies AL, et al
   A cause and protective treatment for acute and progressive disability and grey matter atrophy.
   Brain. 2026;149:1144-1152.
   PubMed         Abstract available
   
   

   
   J Neuroimmunol

5. KHEDR EM, Haridy NA, El-Deen HB, Abdelwarith A, et al
   Tracking the invisible: Impact of disease-modifying therapies on serum neurofilament light chain and clinical outcomes in treatment-naive multiple sclerosis.
   J Neuroimmunol. 2026;417:578928.
   PubMed         Abstract available
   
   

   
   J Neurol

6. ZIVADINOV R, Semy M, Bartnik A, Hildesheim FE, et al
   Dura mater enhancement on 3T MRI is associated with cortical lesion burden in multiple sclerosis.
   J Neurol. 2026;273:251.
   PubMed         Abstract available
   
   
7. JARIUS S, Ruprecht K, Metz I, Konig FB, et al
   An autoantibody signature predictive for multiple sclerosis: evidence at the protein level and association with histopathological lesion types.
   J Neurol. 2026;273:257.
   PubMed         Abstract available
   
   
8. HEGEN H, Fottinger F, Walde J, Berek K, et al
   The role of age in choosing high-efficacy treatment for multiple sclerosis: an Austrian MS Database study.
   J Neurol. 2026;273:262.
   PubMed         Abstract available
   
   

   
   J Neurol Sci

9. HAQ MMU, Shoaib SM
   Comment on "Correlation between blood biomarkers and patient-reported outcomes (PROs) of depression and mental health scores in Individuals with Multiple Sclerosis (iwMS)".
   J Neurol Sci. 2026;485:125900.
   PubMed        
   
   

   
   Mult Scler

10. PIERRET C, Androdias G, Lebrun-Frenay C, Vukusic S, et al
    Impact of cancer on multiple sclerosis-related healthcare and disease-modifying drug use: A multinational cohort study.
    Mult Scler. 2026 Apr 5:13524585261437966. doi: 10.1177/13524585261437966.
    PubMed         Abstract available
    
    
11. GHAJARZADEH M, Mowry EM, Fitzgerald KC, Nourbakhsh B, et al
    Cardiovascular comorbidities are associated with cross-sectional and longitudinal measures of multiple sclerosis fatigue.
    Mult Scler. 2026 Apr 5:13524585261438014. doi: 10.1177/13524585261438014.
    PubMed         Abstract available
    
    

    
    Nat Rev Neurol

12. FYFE I
    Skull bone marrow changes in multiple sclerosis.
    Nat Rev Neurol. 2026 Apr 9. doi: 10.1038/s41582-026-01207.
    PubMed        
    
    

    
    Neurology

13. LANGER-GOULD A, Li BH, Smith JB, Nielsen AS, et al
    Comparative Effectiveness of Rituximab Dosed Every 6 and 12 Months in Relapsing Multiple Sclerosis.
    Neurology. 2026;106:e214917.
    PubMed        
    
    
14. BOURDETTE D, Hartung DM
    Industry Payments to Physicians Alter the Care of Patients With Multiple Sclerosis: It's Time to Cut Financial Ties.
    Neurology. 2026;106:e214920.
    PubMed        
    
    
15. PATEL AN, Kesselheim AS, Rome BN
    Industry Payments and Prescribing of Brand-Name Multiple Sclerosis Medications in Medicare.
    Neurology. 2026;106:e214834.
    PubMed         Abstract available
    
    

    
    Rev Neurol (Paris)

16. KOUBIYR I, Schoonheim MM
    Brain atrophy in multiple sclerosis: Mechanisms, measurement, and clinical translation.
    Rev Neurol (Paris). 2026 Apr 2:S0035-3787(26)00497.
    PubMed         Abstract available
    
    
17. BOURGUIBA-HACHEMI S, Paris J, Gourraud PA, Vince N, et al
    The genetic architecture of multiple sclerosis in 2026: From susceptibility to disease progression.
    Rev Neurol (Paris). 2026 Apr 2:S0035-3787(26)00499.
    PubMed         Abstract available
    
    
18. BARRIE W
    The evolutionary origins of multiple sclerosis.
    Rev Neurol (Paris). 2026 Apr 1:S0035-3787(26)00496.
    PubMed         Abstract available
    
    
19. SORELLA MY, Ding Y, Garcia AM, Ygonia M, et al
    Contrasting genetic architectures of multiple sclerosis susceptibility and outcome phenotypes.
    Rev Neurol (Paris). 2026 Apr 3:S0035-3787(26)00500.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum